Cargando…
Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study
The Duffy antigen receptor for chemokines (DARC) rs12075 polymorphism regulates leukocyte trafficking and proinflammatory chemokine homeostasis. Hepatitis C virus (HCV)-mediated liver fibrosis is associated with an uncontrolled inflammatory response. In this study, we evaluate the association betwee...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523653/ https://www.ncbi.nlm.nih.gov/pubmed/30970632 http://dx.doi.org/10.3390/biom9040143 |
_version_ | 1783419383826087936 |
---|---|
author | Jiménez-Sousa, María Ángeles Gómez-Moreno, Ana Zaida Pineda-Tenor, Daniel Sánchez-Ruano, Juan José Artaza-Varasa, Tomas Martin-Vicente, María Fernández-Rodríguez, Amanda Martínez, Isidoro Resino, Salvador |
author_facet | Jiménez-Sousa, María Ángeles Gómez-Moreno, Ana Zaida Pineda-Tenor, Daniel Sánchez-Ruano, Juan José Artaza-Varasa, Tomas Martin-Vicente, María Fernández-Rodríguez, Amanda Martínez, Isidoro Resino, Salvador |
author_sort | Jiménez-Sousa, María Ángeles |
collection | PubMed |
description | The Duffy antigen receptor for chemokines (DARC) rs12075 polymorphism regulates leukocyte trafficking and proinflammatory chemokine homeostasis. Hepatitis C virus (HCV)-mediated liver fibrosis is associated with an uncontrolled inflammatory response. In this study, we evaluate the association between the DARC rs12075 polymorphism and liver stiffness progression in HCV-infected patients. We carried out a retrospective cohort study (repeated measures design) in 208 noncirrhotic patients with chronic hepatitis C (CHC) who had at least two liver stiffness measurements (LSM) with a separation of at least 12 months. We used generalized linear models to analyze the association between DARC rs12075 polymorphism and outcome variables. During a follow-up of 46.6 months, the percentage of patients with stages of fibrosis F0/F1 decreased (p < 0.001), while LSM values and the percentage of patients with cirrhosis increased (p < 0.001). This pattern of changes was maintained in each of the groups of patients analyzed according to their rs12075 genotypes (AA or AG/GG). However, the variations in liver stiffness characteristics were lower in patients with the rs12075 AG/GG genotype (AG/GG versus AA). Thereby, in the adjusted analysis, patients with the rs12075 AG/GG genotype had a lower risk of an increased value of LSM2/LSM1 arithmetic mean ratio (AMR = 0.83; p = 0.001) and of an increase in LSM ≥ 5 kPa (odds ratio (OR) = 0.28; p = 0.009). Besides, patients with rs12075 AG/GG had a lower risk of cirrhosis progression (OR = 0.24; p = 0.009). No significant associations were found for an increase in LSM ≥ 10 kPa. We found an association between the DARC rs12075 single nucleotide polymorphism (SNP) and CHC progression. Specifically, patients with the DARC rs12075 AG/GG genotype had a lower risk of liver fibrosis progression and development of cirrhosis. |
format | Online Article Text |
id | pubmed-6523653 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65236532019-06-03 Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study Jiménez-Sousa, María Ángeles Gómez-Moreno, Ana Zaida Pineda-Tenor, Daniel Sánchez-Ruano, Juan José Artaza-Varasa, Tomas Martin-Vicente, María Fernández-Rodríguez, Amanda Martínez, Isidoro Resino, Salvador Biomolecules Article The Duffy antigen receptor for chemokines (DARC) rs12075 polymorphism regulates leukocyte trafficking and proinflammatory chemokine homeostasis. Hepatitis C virus (HCV)-mediated liver fibrosis is associated with an uncontrolled inflammatory response. In this study, we evaluate the association between the DARC rs12075 polymorphism and liver stiffness progression in HCV-infected patients. We carried out a retrospective cohort study (repeated measures design) in 208 noncirrhotic patients with chronic hepatitis C (CHC) who had at least two liver stiffness measurements (LSM) with a separation of at least 12 months. We used generalized linear models to analyze the association between DARC rs12075 polymorphism and outcome variables. During a follow-up of 46.6 months, the percentage of patients with stages of fibrosis F0/F1 decreased (p < 0.001), while LSM values and the percentage of patients with cirrhosis increased (p < 0.001). This pattern of changes was maintained in each of the groups of patients analyzed according to their rs12075 genotypes (AA or AG/GG). However, the variations in liver stiffness characteristics were lower in patients with the rs12075 AG/GG genotype (AG/GG versus AA). Thereby, in the adjusted analysis, patients with the rs12075 AG/GG genotype had a lower risk of an increased value of LSM2/LSM1 arithmetic mean ratio (AMR = 0.83; p = 0.001) and of an increase in LSM ≥ 5 kPa (odds ratio (OR) = 0.28; p = 0.009). Besides, patients with rs12075 AG/GG had a lower risk of cirrhosis progression (OR = 0.24; p = 0.009). No significant associations were found for an increase in LSM ≥ 10 kPa. We found an association between the DARC rs12075 single nucleotide polymorphism (SNP) and CHC progression. Specifically, patients with the DARC rs12075 AG/GG genotype had a lower risk of liver fibrosis progression and development of cirrhosis. MDPI 2019-04-09 /pmc/articles/PMC6523653/ /pubmed/30970632 http://dx.doi.org/10.3390/biom9040143 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jiménez-Sousa, María Ángeles Gómez-Moreno, Ana Zaida Pineda-Tenor, Daniel Sánchez-Ruano, Juan José Artaza-Varasa, Tomas Martin-Vicente, María Fernández-Rodríguez, Amanda Martínez, Isidoro Resino, Salvador Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study |
title | Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study |
title_full | Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study |
title_fullStr | Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study |
title_full_unstemmed | Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study |
title_short | Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study |
title_sort | impact of darc rs12075 variants on liver fibrosis progression in patients with chronic hepatitis c: a retrospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523653/ https://www.ncbi.nlm.nih.gov/pubmed/30970632 http://dx.doi.org/10.3390/biom9040143 |
work_keys_str_mv | AT jimenezsousamariaangeles impactofdarcrs12075variantsonliverfibrosisprogressioninpatientswithchronichepatitiscaretrospectivestudy AT gomezmorenoanazaida impactofdarcrs12075variantsonliverfibrosisprogressioninpatientswithchronichepatitiscaretrospectivestudy AT pinedatenordaniel impactofdarcrs12075variantsonliverfibrosisprogressioninpatientswithchronichepatitiscaretrospectivestudy AT sanchezruanojuanjose impactofdarcrs12075variantsonliverfibrosisprogressioninpatientswithchronichepatitiscaretrospectivestudy AT artazavarasatomas impactofdarcrs12075variantsonliverfibrosisprogressioninpatientswithchronichepatitiscaretrospectivestudy AT martinvicentemaria impactofdarcrs12075variantsonliverfibrosisprogressioninpatientswithchronichepatitiscaretrospectivestudy AT fernandezrodriguezamanda impactofdarcrs12075variantsonliverfibrosisprogressioninpatientswithchronichepatitiscaretrospectivestudy AT martinezisidoro impactofdarcrs12075variantsonliverfibrosisprogressioninpatientswithchronichepatitiscaretrospectivestudy AT resinosalvador impactofdarcrs12075variantsonliverfibrosisprogressioninpatientswithchronichepatitiscaretrospectivestudy |